Shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $14.43.
Several brokerages have weighed in on COGT. HC Wainwright lowered their price objective on Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, January 14th. Piper Sandler upgraded Cogent Biosciences to a "strong-buy" rating in a research report on Friday, March 7th. Wedbush reissued a "neutral" rating and set a $11.00 price objective on shares of Cogent Biosciences in a report on Tuesday, February 25th. Scotiabank initiated coverage on shares of Cogent Biosciences in a research report on Friday, March 7th. They set a "sector outperform" rating and a $17.00 target price on the stock. Finally, Robert W. Baird dropped their target price on Cogent Biosciences from $10.00 to $8.00 and set a "neutral" rating for the company in a report on Thursday, February 27th.
View Our Latest Stock Report on COGT
Institutional Investors Weigh In On Cogent Biosciences
Several institutional investors have recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Cogent Biosciences in the fourth quarter valued at about $78,000. Hsbc Holdings PLC purchased a new stake in Cogent Biosciences in the 4th quarter valued at approximately $81,000. KLP Kapitalforvaltning AS acquired a new stake in Cogent Biosciences during the 4th quarter valued at $88,000. E Fund Management Co. Ltd. purchased a new position in Cogent Biosciences during the fourth quarter worth $89,000. Finally, Proficio Capital Partners LLC acquired a new position in shares of Cogent Biosciences in the fourth quarter worth $93,000.
Cogent Biosciences Stock Up 2.3 %
NASDAQ:COGT traded up $0.12 on Thursday, hitting $5.03. The stock had a trading volume of 134,517 shares, compared to its average volume of 1,260,626. The business's fifty day moving average is $6.04 and its 200 day moving average is $8.12. Cogent Biosciences has a 52 week low of $3.72 and a 52 week high of $12.61. The company has a market cap of $572.13 million, a PE ratio of -2.02 and a beta of 1.67.
About Cogent Biosciences
(
Get Free ReportCogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
See Also
Before you consider Cogent Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.
While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
